Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alnylam Pharmaceuticals Inc ALNY

Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for... see more

Recent & Breaking News (NDAQ:ALNY)

Alnylam Announces Appointment of Peter Kellogg to Board of Directors

Business Wire March 8, 2023

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

Business Wire March 1, 2023

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity

Business Wire February 23, 2023

Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Business Wire February 21, 2023

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results

Business Wire February 2, 2023

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates

Business Wire January 8, 2023

Alnylam Announces Updates to its Board of Directors

Business Wire January 5, 2023

Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference

Business Wire January 3, 2023

Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes

Business Wire December 21, 2022

Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day

Business Wire December 15, 2022

Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Business Wire December 8, 2022

Alnylam to Webcast Virtual R&D Day

Business Wire December 8, 2022

Alnylam Ranks #1 on Boston Globe's Top Places to Work List for 2022

Business Wire December 1, 2022

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Business Wire November 9, 2022

Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year

Business Wire October 27, 2022

Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity

Business Wire October 27, 2022

Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results

Business Wire October 13, 2022

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Business Wire October 6, 2022

Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting

Business Wire September 30, 2022

Alnylam Announces New Management Appointments

Business Wire September 21, 2022